Financial Times reported that Tekeda did not move forward with buying Salix, on grounds that Valeant would not provide the pertinent financial data. The key question for Valeant shareholders is whether Tekeda is using tough negotiation tactics or is genuinely serious about buying the GI drug supplier. Chances are good that the two companies are in the early innings of negotiations. Understandably, Valeant management is distracted with many “fires” in the business.Beefing up accountabilityValeant will need to bolster its accounting staff to raise accountability in Salix’s quarterly reporting. Without financial metrics matched to staff performance, the company will continue underperforming.It cannot afford this.Valeant does not need Tekeda to buy Salix right now. It should turn its attention on growing the Salix business. Long time shareholders will remember that effective ads helped grow Xifaxan sales. Since the management changes and focus towards selling assets, sales likely weakened.Tekeda will need to partner with TPG if it wants to put together a serious bid. When it does, then Valeant may re-start negotiations to sell Salix. <img class="chart-posts-item_image-preview" src="https://get.whotrades.com/u5/photo48D3/20013042684-0/original.jpeg" alt="" /> Readers: WhoTrades's launching marketplace. Sign up for the information session. Earn fees by sharing trades with traders.